Emcure Pharmaceuticals Ltd (EMCURE) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Emcure Pharmaceuticals Ltd ₹1,043, price ₹1,951, upside -46.5%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Emcure Pharmaceuticals Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
27‑month range ₹903.73 – ₹2,010 · fair‑value band ₹522.99 – ₹1,340 · the ₹1,951 price screens above the ₹1,043 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Emcure Pharmaceuticals in your weekly email
Every Wednesday you see whether Emcure Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular.
Show more
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Stock analysis
Emcure Pharmaceuticals Ltd (EMCURE) currently trades at ₹1,951, while our model-based Fair Value estimate is ₹1,043, implying the stock looks roughly 87.0% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹1,178 per share, and 0 of the 26 models we run sit above the ₹1,951 price.
Bear case: the Asset-Based group reads lowest at ₹174.85, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹522.99 (bear) to ₹1,340 (bull), the price of ₹1,951 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Emcure Pharmaceuticals Ltd reported revenue of ₹92.0B in FY2026 versus ₹57.7B in FY2022, a compound +12.4%/yr. Reported net income was ₹9.2B in FY2026, compounding +8.7%/yr from FY2022.
Key figures
Market cap ₹370B (≈ $3.9B) · P/E ratio 40.1 · P/S ratio 4.02 · EPS (TTM) ₹48.70 · Dividend yield 0.2% · Net margin 10.0% · Return on equity 19.6% · Return on assets (EBIT) 14.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 3% below its 52-week high and 53% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −47%, EMCURE screens richer than that median.
Fair Value models
Bear ₹522.99Fair Value ₹1,043Bull ₹1,340
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹22.24 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.86/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+17.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+11.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.2%
Dividend (yield on the price)0.2%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 15%
2026 sits 73% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+43.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +38.0% a year for the price and +6.4% for the forecasts.
Compare Emcure Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 619 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−46.5% · Below median
Profitability
Return on equity (TTM)19.6% · Top 25%
Return on assets9.6% · Top 25%
Net margin (TTM)10.0% · Above median
Operating margin (TTM)15.4% · Above median
Growth and dividend
Revenue growth16.7% · Above median
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)40.1× · Pricier than median
P/B7.47× · Priciest 25%
P/S (TTM)4.02× · Pricier than median
P/FCF0.8× · Cheaper than median
EV/EBITDA20.7× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)84· sector 18
PAST (return on equity)78· sector 26
HEALTH (low debt)97· sector 96
DIVIDEND (yield)4· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Emcure Pharmaceuticals Ltd (EMCURE) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹1,043 versus a price of ₹1,951, about −47% upside (overvalued).
What is the fair value of EMCURE?
Our model-based fair value for Emcure Pharmaceuticals Ltd is ₹1,043 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹1,951.
What is the quality score of EMCURE?
Emcure Pharmaceuticals Ltd has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Emcure Pharmaceuticals Ltd (EMCURE)?
Our model-based price target is the fair value of ₹1,043 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario ₹522.99, optimistic scenario ₹1,340. It is a calculation from audited fundamentals, not an analyst target.
What is the Emcure Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at ₹1,043, about −47% upside versus a price of ₹1,951 (overvalued). Cautious scenario ₹522.99, optimistic scenario ₹1,340. The calculation is refreshed regularly with new filings.
What is the revenue of Emcure Pharmaceuticals Ltd (EMCURE)?
Emcure Pharmaceuticals Ltd reported trailing-twelve-month revenue of about ₹92.0B (latest available figure, as of Sep 27, 2026).
Does Emcure Pharmaceuticals Ltd pay a dividend?
Emcure Pharmaceuticals Ltd currently shows a dividend yield of about 0.18% relative to its recent price (as of Sep 27, 2026).
What growth is priced into Emcure Pharmaceuticals Ltd (EMCURE)?
For today's price to be fair in a discounted-cash-flow model, Emcure Pharmaceuticals Ltd would have to grow free cash flow by +43.7 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +12.4 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of EMCURE use?
Our models discount Emcure Pharmaceuticals Ltd at 12.4 %: a base by market capitalisation (mid), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Emcure Pharmaceuticals Ltd that is +43.7 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Emcure Pharmaceuticals Ltd (EMCURE) delivered so far?
Over the past 4 years revenue at Emcure Pharmaceuticals Ltd grew +12.4 % a year. The price currently implies +43.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Emcure Pharmaceuticals Ltd (EMCURE) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Emcure Pharmaceuticals Ltd (+43.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Emcure Pharmaceuticals Ltd (EMCURE)?
The free-cash-flow yield on the price is 1.33 %: that much free cash flow Emcure Pharmaceuticals Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Emcure Pharmaceuticals Ltd (EMCURE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emcure Pharmaceuticals Ltd it is ₹1,043 per share (as of Sep 27, 2026), against a price of ₹1,951. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Emcure Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, EMCURE trades above its calculated fair value: price ₹1,951, fair value ₹1,043, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EMCURE?
No. The price is what the market pays today (₹1,951); the fair value is what the company's own numbers justify (₹1,043). For Emcure Pharmaceuticals Ltd the two are ₹907.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Emcure Pharmaceuticals Ltd worth?
The market values Emcure Pharmaceuticals Ltd at about ₹370B (market capitalisation, as of Sep 27, 2026). Per share that is ₹1,951; our models calculate a fair value of ₹1,043 per share.
What do the bullish and bearish scenarios say about EMCURE?
Our models span a range for Emcure Pharmaceuticals Ltd: cautious scenario ₹522.99, base ₹1,043, optimistic ₹1,340 per share (as of Sep 27, 2026, price ₹1,951). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EMCURE?
Emcure Pharmaceuticals Ltd trades at a price-to-earnings ratio of 40.1 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,043 is built from several models across several years. Other multiples: P/B 7.5, P/S 4.0, EV/EBITDA 20.7.
How solid is the balance sheet of Emcure Pharmaceuticals Ltd (EMCURE)?
Balance-sheet figures for Emcure Pharmaceuticals Ltd (as of Sep 27, 2026): return on equity 19.6%, debt of 0.05 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is EMCURE from its 52-week high?
Emcure Pharmaceuticals Ltd trades at ₹1,951, about 3% below its 52-week high of ₹2,010 and 53% above the low of ₹1,272 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,043 is for.
Which stocks are comparable to Emcure Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Emcure Pharmaceuticals Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price ₹1,951, calculated fair value ₹1,043 (−47%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EMCURE calculated?
We run Emcure Pharmaceuticals Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,043, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Emcure Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Emcure Pharmaceuticals Ltd (EMCURE)?
The closing price on Sep 25, 2026 was ₹1,951. Our model-based fair value is ₹1,043, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Emcure Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (₹1,340). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹522.99 to ₹1,340) leaves room in how you read the outcome.
Key figures of Emcure Pharmaceuticals Ltd
How large is the market capitalisation of Emcure Pharmaceuticals Ltd (EMCURE)?
The market capitalisation of Emcure Pharmaceuticals Ltd is ₹370B (≈ $3.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Emcure Pharmaceuticals Ltd (EMCURE)?
The price-to-sales ratio of Emcure Pharmaceuticals Ltd is 4.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Emcure Pharmaceuticals Ltd (EMCURE)?
Earnings per share at Emcure Pharmaceuticals Ltd are ₹48.70 (price ÷ EPS = P/E 40.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Emcure Pharmaceuticals Ltd (EMCURE)?
The dividend yield of Emcure Pharmaceuticals Ltd is 0.2% (payout 7.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Emcure Pharmaceuticals Ltd (EMCURE)?
The net margin of Emcure Pharmaceuticals Ltd is 10.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Emcure Pharmaceuticals Ltd (EMCURE)?
The return on equity (ROE) of Emcure Pharmaceuticals Ltd is 19.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Emcure Pharmaceuticals Ltd (EMCURE)?
On an EBIT basis the return on assets of Emcure Pharmaceuticals Ltd is 14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Emcure Pharmaceuticals Ltd (EMCURE)?
The operating margin of Emcure Pharmaceuticals Ltd is 15.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Emcure Pharmaceuticals Ltd (EMCURE)?
Revenue at Emcure Pharmaceuticals Ltd is growing +16.7% versus a year earlier (3y avg +15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Emcure Pharmaceuticals Ltd (EMCURE)?
Earnings per share at Emcure Pharmaceuticals Ltd are growing +28.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Emcure Pharmaceuticals Ltd (EMCURE) carry?
The net debt of Emcure Pharmaceuticals Ltd is ₹13.7B (fiscal year 2026, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Emcure Pharmaceuticals Ltd in the live analysis
One click puts Emcure Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
